Equity Research Report: Unjha Formulations Ltd.
Date: February 6, 2026
Sector: Pharmaceuticals / Ayurvedic Formulations
CMP (Current Market Price): ₹23.00 (Approx)
Market Cap: ₹10.30 Cr (Nano Cap)
⚠️ CRITICAL WARNING:
Yeh ek Nano-Cap / Penny Stock hai (Market Cap < ₹15 Cr). Isme liquidity bahut kam hoti hai aur volatility extreme hoti hai. Aisi companies me “Operator Activity” ka risk sabse zyada hota hai.
1️⃣ Business Model & Work
- Core Business: Unjha Formulations Ltd. pharmaceutical aur ayurvedic medicines ki manufacturing me involved hai.
- Key Products: Company mainly Isabgol (Psyllium Husk) based products banati hai. Iske alawa tablets, capsules, oral liquids aur dry powders bhi manufacture karti hai.
- Focus Area: Ayurvedic formulations aur generic medicines. Company ka base Gujarat (Sidhpur/Patan) me hai.
- Scale: Operations bahut chote scale par hain (Micro-enterprise level).
2️⃣ Industry & Sector Analysis
- Sector Status: Pharma aur Ayurveda sector India me grow kar raha hai, lekin yeh growth mainly established brands (Dabur, Himalaya, Zandu) aur large exports ke through ho rahi hai.
- Micro-Pharma Struggle: Choti pharma companies ko raw material costs aur strict regulatory compliance (USFDA/WHO-GMP) maintain karne me mushkil hoti hai.
- Competition: Isabgol market me local players aur unorganized sector se huge competition hai. Koi bada competitive advantage visible nahi hai.
3️⃣ Latest Financial Performance (STRICT DATA ANALYSIS)
⚠️ Data Note: Financials highly volatile hain. Kabhi profit jump karta hai, kabhi loss me chala jata hai.
Financial Trend (Figures in ₹ Cr approx):
| Metric | FY 2024 (Annual) | FY 2025 (Annual) | Latest Qtr (Sep ’25) | TTM (Trailing 12M) |
| Revenue (Sales) | 18.50 | 13.86 | 4.29 | ~14.50 |
| Net Profit (PAT) | 0.28 | 0.41 | 0.82 | ~1.00 – 1.20 |
| OPM % | 3% | 3.75% | 18.4% (Abnormal Spike) | ~7-8% |
| EPS (₹) | 0.62 | 0.92 | 1.83 | ~2.30 |
- Observation:
- Inconsistent Revenue: FY24 me sales ₹18 Cr thi jo FY25 me girkar ₹13.8 Cr reh gayi. Growth consistent nahi hai.
- Margin Volatility: Sep ’25 quarter me Operating Margin achanak 18% ho gaya, jabki historical average 3-4% rehta hai. Yeh “One-time adjustment” ya “Inventory gain” ho sakta hai, sustainable nahi lagta.
- Small Numbers: Profit numbers lakhs me hain, crores me mushkil se pahunchte hain.
4️⃣ Management & Shareholding (Latest Available – RED FLAG 🚩)
- Promoter Holding:36.92% (Low & Warning).
- Analysis: Micro-cap companies me agar promoter holding < 50% hai, to yeh bada risk hai. Iska matlab hai ki promoters ka khud ka paisa business me kam laga hai.
- FII / DII Holding: 0.00%. No institutional interest.
- Public Holding: 63.08%. Ownership mainly retail aur HNIs (High Net-worth Individuals) ke paas hai, jo stock ko manipulation ke liye vulnerable banata hai.
5️⃣ Valuation (Latest Market Data)
- PE Ratio: ~10x.
- Current earnings ke hisab se stock sasta lag sakta hai (PE 10), lekin kyunki earnings reliable nahi hain (sudden margin spike), is PE par trust nahi kiya ja sakta.
- Price to Book (PB): ~2.3x.
- Stock apni book value (~₹9-10) se dugne daam par trade kar raha hai.
- Comparison: Peer comparison (Sun Pharma, Cipla) se karna illogical hai. Iska muqabla sirf local unlisted pharma units se hai.
6️⃣ Future Growth Triggers (3–5 Years)
- Ayurveda Trend: Agar company apne “Isabgol” brand ko export market me scale kar paye, to growth aa sakti hai. Currently, export numbers significant nahi dikh rahe.
- Capacity Expansion: Public domain me koi badi Capex (expansion) announcement nahi hai.
7️⃣ Present Situation (Current Outlook)
- Stock Phase:Range Bound / Volatile.
- Stock ₹20 – ₹30 ki range me ghum raha hai.
- Recent quarter (Sep ’25) ke acche numbers (Profit ₹0.82 Cr) ki wajah se stock me thodi buying interest dikhi hai, lekin volume bahut kam hai.
- Surveillance History: Yeh stock past me BSE ke ASM/GSM (Surveillance Measures) list me raha hai, jo indicate karta hai ki regulator ko iski price movement par shak tha.
8️⃣ Risk & Red Flags (Must Read)
- Nano-Cap Risk: Market Cap sirf ₹10 Cr hai. Ek bada investor agar exit karega to stock me Lower Circuit lag jayenge.
- Low Promoter Stake: 36% holding confidence nahi deti.
- History of Surveillance: ASM/GSM me bar-bar aana ek negative governance signal hai.
- Unstable Margins: 3% se seedha 18% margin jump hona suspicious hai jab tak ki koi solid reason (new product launch) na ho.
9️⃣ Final Verdict
Summary:
- Unjha Formulations ek extremely small pharma company hai with inconsistent track record.
- Recent quarter results acche hain (High Margins), lekin historical data weak hai.
- Promoter holding (36%) kam hai jo long-term trust build nahi karti.
Recommendation:
- Conservative / Long-Term Investors: STRICTLY AVOID. Pharma sector me wealth create karni hai to quality mid-caps (jaise Eris Lifesciences, JB Chemicals) dekhein, is penny stock me nahi.
- Aggressive / High Risk Investors: Sirf tabhi dekhein agar aap short-term “News based trading” kar rahe hain. Recent results ke baad thoda momentum aa sakta hai, lekin profit book karke nikalna zaroori hai. Hold karne layak stock nahi hai.
Target Range: Speculative. ₹18 (Support) – ₹28 (Resistance).
Next Step for You:
Would you like me to analyze a Small-Cap Pharma stock (like Lincoln Pharma or Jenburkt Pharma) that is profitable, dividend-paying, and safe for investment?
Disclaimer: Ye article sirf educational purpose ke liye hai. Kisi bhi nivesh se pehle apne Financial Advisor se salah zarur lein.